Prenetics delivered the growth investors have come to expect from IM8, but it attached a much larger bill to it. The company reported a loss of $0.93 per share for the September quarter, missing the -$0.73 consensus by 27.4%. Earnings fell 126.8% year over year. Revenue of $64.11 million beat the $63.19 million consensus by 1.5% and grew 172.2% year over year. (The company cites roughly 228% growth, which reflects a different prior-year comparison basis after its discontinued-operations re-presentation.) The central tension is plain. Top-line execution and unit economics improved, yet management roughly tripled its second-half Adjusted EBITDA loss guidance to $30-35 million from $8-12 million. The profitability timeline that anchored the story earlier in the year is now open-ended.
The quality of the quarter depends on which line you read. IM8 revenue reached $62.9 million, up about 40% sequentially and above the top of guidance. September alone produced $23.7 million, an annualized run-rate of about $284 million, compared with $251 million in July and $186 million in May. Adjusted EBITDA loss narrowed to $12.7 million, or 20% of revenue, from 39% in Q2. Contribution margin edged up to 48% from 46%.
The IFRS picture is weaker. The net loss widened to $25.4 million from about $9 million in Q2, including a $7.2 million non-cash warrant fair-value loss. Gross margin slipped to 64% on a $1.3 million write-off of older formulations. The touted positive Adjusted Free Cash Flow of $4.1 million deserves scrutiny. Operating cash burn was $27.5 million, double Q2's $13.7 million, and the positive figure exists only because of $31.6 million in net draws on the General Catalyst facility. That facility now carries $34.7 million of borrowings plus a repayment premium.
The call preserved a credible unit-economics argument for spending more:
- **Customer acquisition cost:** CAC fell for a second straight quarter, to about $285 from $301, even as acquisition spend reached roughly $40 million.
- **New customers:** Prenetics added a record 137,892 new customers.
- **Subscriptions:** Active subscriptions climbed to about 160,000 from 140,000 last quarter and 82,000 in Q1.
- **Cohort returns:** Lifetime gross profit per acquisition dollar improved to $1.68 from $1.52. The first full-quarter cohort has returned about 4.1x its acquisition cost.
The forward data is less clean, however. August-September CAC ran near $310 versus July's $239. Management guided Q4 CAC to about $300, plus or minus 10-15%, as holiday ad auctions intensify. The implied Q4 Adjusted EBITDA loss of roughly $17-22 million would be well above Q3's.
The catalyst list grew, but so did the slippage. New items include a 10-year Care Bears license with Authentic Brands Group, which becomes a strategic shareholder, an NBA nutrition partnership across Australia and Southeast Asia, and planned retail and China entry by end-2027. Management also introduced a first long-term framework targeting 15-25% Adjusted EBITDA margins, though without a timeline. Against that, several launches slipped:
- Hydration moved to Q1 2027 from Q4 2026.
- Gummies, now Care Bears, moved to Q2 2027.
- Creatine has dropped off the roadmap.
FY2026 revenue guidance of $220-230 million and the FY2027 IM8 target of $400 million or more were only reaffirmed, after raises on each of the prior two calls. The implied full-year 2026 Adjusted EBITDA loss of about $55-60 million compares with an original $16-20 million. A CFO transition on December 31 adds another variable.
The market had already been marking the story down. Shares at $16.33 are 16.7% below the $19.60 open following the August report and about 16% under the 200-day moving average. They are 40% off the $27.24 52-week high set on September 2, and only about 11% above the November 5 low of $14.69. Investor sentiment remains firmly positive but cooled, from 0.89 to 0.81 ahead of the report, a modest erosion rather than a capitulation. The trend readings are mixed: sequential growth and momentum are positive, while price and AVWAP remain negative. That fits a business whose operating trajectory is improving even as the stock has lost ground since August.
The bottom line is that Prenetics executed on growth, CAC, and cohort returns, then asked shareholders to accept substantially deeper losses and financing-dependent cash flow to press the advantage. Bulls have real evidence that incremental customers pay back. Bears have legitimate ammunition in the EPS miss, the reset EBITDA path, delayed launches, rising Q4 CAC risk, and the absence of a revenue raise. Until the larger investment translates into a raised revenue outlook, the stock's position well below its 200-day average suggests investors want proof, not promises.